✦ LIBER ✦

Bendamustine in Patients With Rituximab-Refractory Indolent and Transformed Non-Hodgkin's Lymphoma: Results From a Phase II Multicenter, Single-Agent Study

✍ Scribed by Friedberg, J. W.; Cohen, P.; Chen, L.; Robinson, K. S.; Forero-Torres, A.; La Casce, A. S.; Fayad, L. E.; Bessudo, A.; Camacho, E. S.; Williams, M. E.; van der Jagt, R. H.; Oliver, J. W.; Cheson, B. D.

Book ID: 118016784
Publisher: American Society of Clinical Oncology
Year: 2008
Tongue: English
Weight: 118 KB
Volume: 26
Category: Article
ISSN: 0732-183X
DOI: 10.1200/jco.2007.12.5070

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Bendamustine is effective therapy in pat

Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma : Results from a Multicenter Study

✍ Brad S. Kahl; Nancy L. Bartlett; John P. Leonard; Ling Chen; Kristen Ganjoo; Mic 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 186 KB

Phase II Multicenter Study of Bendamusti

Phase II Multicenter Study of Bendamustine Plus Rituximab in Patients With Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin's Lymphoma

✍ Robinson, K. S.; Williams, M. E.; van der Jagt, R. H.; Cohen, P.; Herst, J. A.; 📂 Article 📅 2008 🏛 American Society of Clinical Oncology 🌐 English ⚖ 119 KB

Rituximab monotherapy with eight weekly

Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab: A multicenter phase II study

✍ Kensei Tobinai; Tadahiko Igarashi; Kuniaki Itoh; Mitsutoshi Kurosawa; Hirokazu N 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 248 KB

A phase II study of Xcellerated T cells™

A phase II study of Xcellerated T cells™ in patients with relapsed or refractory indolent non-Hodgkin’s lymphoma (NHL)

✍ J.G. Gribben; N.L. Bartlett; J.J. Stephenson; M.S. Milder; R.V. Boccia; C. Redfe 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 53 KB

Rituximab as first-line and maintenance

Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: Interim follow-up of a multicenter phase II trial

✍ John D Hainsworth 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 73 KB

Durable complete responses from therapy

Durable complete responses from therapy with combined epratuzumab and rituximab : Final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma

✍ John P. Leonard; Stephen J. Schuster; Christos Emmanouilides; Felix Couture; Nic 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB

## Abstract ## BACKGROUND. In this international, multicenter trial, the authors evaluated rituximab (anti‐CD20) plus epratuzumab (anti‐CD22) in patients with postchemotherapy relapsed/refractory, indolent non‐Hodgkin lymphoma (NHL), including long‐term efficacy. ## METHODS. Forty‐nine patients